Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 302.70% | 26.39% | -16.47% | -8.94% | 1.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.43% | 23.41% | -23.65% | -17.36% | 2.65% |
| Operating Income | -170.63% | 15.88% | 23.65% | 17.36% | -2.65% |
| Income Before Tax | -151.98% | 8.86% | 22.44% | 14.28% | -33.89% |
| Income Tax Expenses | -187.51% | 0.00% | 83.47% | 83.47% | 83.47% |
| Earnings from Continuing Operations | -144.19% | 8.63% | 21.07% | 12.95% | -34.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,056.07% | 128.67% | 173.31% | -- | -- |
| Net Income | -94.49% | 15.84% | 26.24% | 16.87% | -27.77% |
| EBIT | -170.63% | 15.88% | 23.65% | 17.36% | -2.65% |
| EBITDA | -155.36% | 21.59% | 23.65% | 17.36% | -2.65% |
| EPS Basic | 25.41% | 70.67% | 70.93% | 49.02% | 5.27% |
| Normalized Basic EPS | 27.55% | 74.68% | 70.99% | 49.86% | 29.24% |
| EPS Diluted | 25.41% | 70.67% | 70.93% | 49.02% | 5.27% |
| Normalized Diluted EPS | 27.55% | 74.68% | 70.99% | 49.86% | 29.24% |
| Average Basic Shares Outstanding | 160.76% | 186.89% | 137.75% | 58.27% | 34.86% |
| Average Diluted Shares Outstanding | 160.76% | 186.89% | 137.75% | 58.27% | 34.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |